274 related articles for article (PubMed ID: 25962513)
1. Body mass index and response to infliximab in rheumatoid arthritis.
Ottaviani S; Gardette A; Tubach F; Roy C; Palazzo E; Gill G; Meyer O; Dieudé P
Clin Exp Rheumatol; 2015; 33(4):478-83. PubMed ID: 25962513
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and response to abatacept in rheumatoid arthritis.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Meyer A; Sibilia J; Fautrel B; Palazzo E; Dieudé P
Clin Rheumatol; 2016 Apr; 35(4):857-61. PubMed ID: 26801332
[TBL] [Abstract][Full Text] [Related]
4. Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years.
Iannone F; Salaffi F; Marchesoni A; Gorla R; Atzeni F; Govoni M; Gremese E; Lapadula G; On Behalf Of Gisea Gruppo Italiano di Studio Sulle Early Arthritides A
Clin Exp Rheumatol; 2015; 33(4):524-30. PubMed ID: 26087761
[TBL] [Abstract][Full Text] [Related]
5. Body Mass Index and response to rituximab in rheumatoid arthritis.
Ottaviani S; Gardette A; Roy C; Tubach F; Gill G; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Dec; 82(6):432-6. PubMed ID: 26184536
[TBL] [Abstract][Full Text] [Related]
6. Body mass index and clinical response to infliximab in rheumatoid arthritis.
Klaasen R; Wijbrandts CA; Gerlag DM; Tak PP
Arthritis Rheum; 2011 Feb; 63(2):359-64. PubMed ID: 21279992
[TBL] [Abstract][Full Text] [Related]
7. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
8. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.
Sandberg ME; Bengtsson C; Källberg H; Wesley A; Klareskog L; Alfredsson L; Saevarsdottir S
Ann Rheum Dis; 2014 Nov; 73(11):2029-33. PubMed ID: 24818635
[TBL] [Abstract][Full Text] [Related]
9. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients.
Valor L; Hernández-Flórez D; de la Torre I; Del Río T; Nieto JC; González C; López-Longo FJ; Monteagudo I; Llinares F; Rosas J; Garrido J; Naredo E; Carreño L
Clin Exp Rheumatol; 2015; 33(6):805-11. PubMed ID: 26314759
[TBL] [Abstract][Full Text] [Related]
10. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
11. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
[TBL] [Abstract][Full Text] [Related]
12. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
13. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.
Schulman E; Bartlett SJ; Schieir O; Andersen KM; Boire G; Pope JE; Hitchon C; Jamal S; Thorne JC; Tin D; Keystone EC; Haraoui B; Goodman SM; Bykerk VP;
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1185-1191. PubMed ID: 29193840
[TBL] [Abstract][Full Text] [Related]
14. The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients.
Cheng P; Wang J
J Clin Lab Anal; 2020 Aug; 34(8):e23329. PubMed ID: 32281166
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; de Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2009; 27(2):222-8. PubMed ID: 19473561
[TBL] [Abstract][Full Text] [Related]
16. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
18. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
19. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
